Invizyne Technologies (IZTC) Competitors $10.07 -0.03 (-0.25%) As of 08/1/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock IZTC vs. MNPR, DRUG, ACB, DMAC, GALT, CLDI, TKNO, ALMS, LRMR, and TVRDShould you be buying Invizyne Technologies stock or one of its competitors? The main competitors of Invizyne Technologies include Monopar Therapeutics (MNPR), Bright Minds Biosciences (DRUG), Aurora Cannabis (ACB), DiaMedica Therapeutics (DMAC), Galectin Therapeutics (GALT), Calidi Biotherapeutics (CLDI), Alpha Teknova (TKNO), Alumis (ALMS), Larimar Therapeutics (LRMR), and Tvardi Therapeutics (TVRD). These companies are all part of the "pharmaceutical products" industry. Invizyne Technologies vs. Its Competitors Monopar Therapeutics Bright Minds Biosciences Aurora Cannabis DiaMedica Therapeutics Galectin Therapeutics Calidi Biotherapeutics Alpha Teknova Alumis Larimar Therapeutics Tvardi Therapeutics Monopar Therapeutics (NASDAQ:MNPR) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability. Do analysts rate MNPR or IZTC? Monopar Therapeutics currently has a consensus price target of $60.00, indicating a potential upside of 47.60%. Given Monopar Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Monopar Therapeutics is more favorable than Invizyne Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monopar Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer MNPR or IZTC? In the previous week, Monopar Therapeutics had 1 more articles in the media than Invizyne Technologies. MarketBeat recorded 1 mentions for Monopar Therapeutics and 0 mentions for Invizyne Technologies. Monopar Therapeutics' average media sentiment score of 0.00 equaled Invizyne Technologies'average media sentiment score. Company Overall Sentiment Monopar Therapeutics Neutral Invizyne Technologies Neutral Which has better valuation & earnings, MNPR or IZTC? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonopar TherapeuticsN/AN/A-$15.59M-$3.48-11.68Invizyne TechnologiesN/AN/AN/AN/AN/A Do institutionals and insiders hold more shares of MNPR or IZTC? 1.8% of Monopar Therapeutics shares are held by institutional investors. 20.5% of Monopar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is MNPR or IZTC more profitable? Invizyne Technologies' return on equity of 0.00% beat Monopar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Monopar TherapeuticsN/A -55.39% -51.53% Invizyne Technologies N/A N/A N/A SummaryMonopar Therapeutics beats Invizyne Technologies on 6 of the 8 factors compared between the two stocks. Get Invizyne Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for IZTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IZTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IZTC vs. The Competition Export to ExcelMetricInvizyne TechnologiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$62.99M$295.95M$5.57B$9.47BDividend YieldN/AN/A4.31%4.13%P/E RatioN/AN/A29.3723.99Price / SalesN/A448.74444.1896.63Price / CashN/A22.4435.8458.51Price / BookN/A10.208.085.58Net IncomeN/A-$111.61M$3.26B$265.35M7 Day Performance-0.25%4.28%0.45%-0.07%1 Month Performance1.66%18.89%4.83%1.76%1 Year PerformanceN/A4.21%30.28%25.39% Invizyne Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IZTCInvizyne TechnologiesN/A$10.08-0.2%N/AN/A$62.99MN/A0.0029Positive NewsGap UpMNPRMonopar Therapeutics1.9703 of 5 stars$39.72-1.8%$60.00+51.1%+1,275.4%$243.09MN/A-11.4110Upcoming EarningsGap UpDRUGBright Minds Biosciences2.2441 of 5 stars$34.64-2.2%$83.25+140.3%+3,195.4%$242.49MN/A-95.68N/ANews CoverageUpcoming EarningsACBAurora Cannabis0.5342 of 5 stars$4.20-8.8%N/A-27.9%$235.97M$246.72M38.141,130News CoverageGap DownDMACDiaMedica Therapeutics1.4518 of 5 stars$4.56+1.4%$10.75+136.0%+40.9%$233.90MN/A-7.0720Upcoming EarningsGap UpGALTGalectin Therapeutics2.4675 of 5 stars$3.68-0.4%$6.00+63.2%+75.3%$232.65MN/A-5.119News CoverageUpcoming EarningsCLDICalidi Biotherapeutics0.2641 of 5 stars$6.40-11.8%N/A-70.2%$232.24MN/A0.0038Short Interest ↑TKNOAlpha Teknova2.3639 of 5 stars$4.35+1.2%$10.00+129.9%+11.8%$230.59M$37.74M-8.99240ALMSAlumis2.5651 of 5 stars$4.31+2.6%$19.80+359.4%-64.4%$229.61MN/A0.00N/AUpcoming EarningsLRMRLarimar Therapeutics2.8024 of 5 stars$3.59-4.1%$18.50+416.0%-50.7%$229.55MN/A-2.4130Insider TradeTVRDTvardi TherapeuticsN/A$24.52-5.7%$64.25+162.0%N/A$229.51M$7.14M0.0080 Related Companies and Tools Related Companies Monopar Therapeutics Alternatives Bright Minds Biosciences Alternatives Aurora Cannabis Alternatives DiaMedica Therapeutics Alternatives Galectin Therapeutics Alternatives Calidi Biotherapeutics Alternatives Alpha Teknova Alternatives Alumis Alternatives Larimar Therapeutics Alternatives Tvardi Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IZTC) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invizyne Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invizyne Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IZTC Stock Alerts